Obesity
Conditions
Brief summary
The aim of this study is to assess the effect of a food supplement containing extracts of carrot and rose hip seeds on the weight of volunteers with overweight or moderate obesity.
Interventions
Sponsors
Institut Pasteur de Lille
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI between 25 and 35 kg / m² (limits excluded), * Having a fat mass (measured by impedance balance in kg) according to the following table: Men 18-29 years : ≥ 21.2 kg; Men 30-49 years : ≥ 21.6 kg; Men 50-65 years : ≥ 23.8 kg; Women 18-29 years : ≥ 31.4 kg; Women30-49 years : ≥ 31.8 kg; Women 50-65 years : ≥ 33.9 kg. * Willing to observe dietetic plan in accordance with dietitian evaluation, * Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form, * Affiliated with a social security scheme.
Exclusion criteria
* Dyslipidemia or hyperlipidemia: * Fasting total cholesterol ≥ 3.0 g / L * Fasting triglycerides\> 2.5 g / L * with heterozygous familial hypercholesterolemia, * Diabetes treated or not with medication, * With severe hepatic and / or renal impairment, liver enzyme level (ALT and / or AST) greater than 2.5 times the upper normal limit, * TSH abnormal or not stable for at least 3 months, * History of cardiac disease (heart attack, stroke, coronary artery disease) or chronic inflammatory disease in the previous 6 months, * With cancer or having had cancer in the 3 years preceding the study, with the exception of basal cell cancers of the skin, * Taking drugs known to have an impact on weight management (corticosteroids, neuroleptics, anti-HIV triple therapy, etc.) in the month preceding inclusion and / or likely to consume them during the test, * Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study, * Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression, * Weight loss treatment in the previous 6 months or having followed a specific treatment promoting weight loss, * Non stable weight during the last 6 months (\>5% change in total weight), * With metal implant (to allow DEXA measurement), * Blood donation in the month before the start of the study and during the study, * Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and / or likely to take during the test, * Following or having followed a hypocaloric diet (energy intake \<1,500 kCal / day) in the month preceding inclusion and / or likely to undertake this diet during the test, * Following a particular diet (vegan), * Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting), * Intense sport exercise practice (physical activity more than 4 hours per week) or not willing to maintain their exercise practises stable during the test, * Smoking more than 5 cigarettes per day, unstable cigarettes consumption, or smoking cessation during 6 months preceding the inclusion or during the test, * Bariatric surgery or who has a gastroplasty ring, * Consuming more than 2 (women) or 3 (men) standard drinks of alcoholic beverage daily, * Consuming illicit drugs, * Using topical anti-cellulite treatments, * For woman: Pregnant or planned to become, breastfeeding, with non-effective contraception, * Known allergy to one of the component of the supplement (carrot and rose hip), * Suffering from serious illnesses such as cancer, recent myocardial infarction, serious digestive pathologies or others diseases found to be inconsistent with the conduct of the study by the investigator, * Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, * Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision, * Presenting a psychological or linguistic incapability to sign the informed consent, * Any other condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline weight at 3 months | 0 month (inclusion), 3 months | Weight (unit: kg) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thyroid Stimulating Hormone | 0 month (inclusion), 3 months | TSH (Thyroid Stimulating Hormone) (unit: mUI/l) |
| Body mass composition by DEXA (dual energy x-ray absorptiometry) | 0 month (inclusion), 3 months | Lean body mass, total fat mass, subcutaneous fat mass, visceral fat mass (unit: g) |
| Anthropometric parameters | 0 month (inclusion), 1 month, 2 months, 3 months | Hip circumference, waist circumference and thigh circumference (unit: cm) |
| Fasting glycemia | 0 month (inclusion), 3 months | Carbohydrate metabolism: Fasting glycemia (unit: g/l) |
| Insulinemia | 0 month (inclusion), 3 months | Carbohydrate metabolism: Insulinemia (unit: mU/l) |
| HbA1c | 0 month (inclusion), 3 months | Carbohydrate metabolism: HbA1c (unit: percent) |
| HOMA index | 0 month (inclusion), 3 months | Carbohydrate metabolism: determination of the HOMA index (calculated) |
| Lipid metabolism | 0 month (inclusion), 3 months | Total cholesterol, HDL, LDL, Triglycerides (unit: g/l) |
| Free fatty acids | 0 month (inclusion), 3 months | Lipid metabolism: free fatty acids (unit: micromol/l) |
| Blood count | 0 month (inclusion), 3 months | Blood parameters: Blood count (unit: G/L) |
| Transaminases | 0 month (inclusion), 3 months | Hepatic metabolism: ASAT/ALAT (unit: UI/l) |
| Sedimentation rate | 0 month (inclusion), 3 months | Blood parameters: Sedimentation rate (unit: mm) |
| High sensible C-reactive protein | 0 month (inclusion), 3 months | CRPhs (high sensible C-reactive protein) (unit: mg/l) |
| Heart rate | 0 month (inclusion), 1 month, 2 months, 3 months | Hemodynamic parameters: Heart rate (unit: Pul/min) |
| Blood pressure | 0 month (inclusion), 1 month, 2 months, 3 months | Hemodynamic parameters: Systolic blood pressure (unit: mm Hg) and Diastolic blood pressure (unit: mm Hg) |
| Body mass composition by impedancemetry | 0 month (inclusion), 1 month, 2 months, 3 months | Lean body mass and total fat mass (unit: percent) |
| Weight | 0 month (inclusion), 1 month, 2 months, 3 months | Anthropometric parameters: weight (unit: kg) |
| Height | 0 month (inclusion), 1 month, 2 months, 3 months | Anthropometric parameters: height (unit: cm) |
| Body Mass Index | 0 month (inclusion), 1 month, 2 months, 3 months | Anthropometric parameters: determined Body Mass Index (unit: kg/m²) |
| Hepatic metabolism | 0 month (inclusion), 3 months | Creatinine (unit: mg/l) |
Countries
France
Outcome results
None listed